Rheumnow Podcast
RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

September 24, 2021

New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields.

In this episode, Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Study of 435 #SLE pts seen during the pandemic. Comparing those seen F2F vs telemedicine, there was no significant difference in SLE disease activity (by SLEDAI-2K) or SLE flare rates or steroid prescribing between visit types https://bit.ly/39wWoQ6

Encouraging DBRPCT of Rituximab in #PMR: 116 screened, 49 enrolled, 47 completed: 23 on RTX vs 24 on PBO. Steroid-free remission at 21 wks seen with 11/23 (48%) RTX pts vs 5/24 (21%) on PBO (p=0·049). Infusion Rxns: 10 RTX vs 3 PBO); 1 SAE (PE) on RTX https://bit.ly/3lSI0rj

Pregnancies exposed to ixekizumab (from Eli Lilly Global Safety Database) found 193 pts with psoriasis, PsA, or axSpA who were IXE exposed. Live births reported for 53.8 and 61.1% of known outcomes. No congenital malformations seen. https://t.co/M1rvCH81hT

FDA approves Jakafi for chronic GVHD. Ruxolitinib (Jakafi, Incyte), an oral Janus kinase 1/2 inhibitor, previously received approval for treatment of patients aged 12 years or older with steroid-refractory acute GVHD. https://t.co/isItDebNZ8

Retrosp. review of 10–24 yr olds w/ newly Dx #SLE shows 78% given steroid-sparing DMARDs by year 1; Most (69%) given HCQ & fewer (34%) given other immunosuppressants. Adults less likely to recv immDMARDs @1 yr https://t.co/aLi6FXlMd3

Case controlled study shows CPPD pts have no higher risk for MACE. 23,124 CPPD vs 86,629 non-CPPD, w/ ⋗ 250,000 Pt-Yrs FU. CPPD MACE risk not increased (HR 0.98), but there was incr risk of MI, CVA & acute coronary syndr. https://t.co/pgmZBxTg9O

Trade names: Generic PFIZER = Comirnaty; MODERNA= Spikevax Moderna; J&J (pending) https://t.co/MM7XiSCczl

Prospective study of 77 RA patients in remission -- ⋗ vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7.8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne

Dr. Calabrese shares his Delta COVID-19 breakthrough story on the blog today. https://t.co/timjB2YPys

BMJ Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were ⋗14 days after 2nd dose Addendum: COVID deaths increased w/ age, deprivation, male, Indian & Pakistanis. Highest risk w/ Down’s syndr (HR 12.7), renal transplant (8.1), sickle cell (7.7), Nursing home (4.1), chemotherapy (4.3), HIV/AIDS (3.3), liver cirrhosis (3), CNS dz (2.6) Addendum: Other conditions w/ a 1.2-2 fold higher risk of COVID death (admission) were CKD, hematologic cancer, epilepsy, COPD, CVD, stroke, atrial fibrillation, CHF, thromboembolism, PVD, type 2 diabetes. https://t.co/bbDsb1zLhX

Claims case-controlled study shows statin use does not increase the risk of #RA - 32,726 RA and matched controls ; statin use (34 vs 32%) slightly increased RA risk (OR 1.12, 1.06–1.18), but signif lost after correcting for hyperlipidemia https://t.co/EcTlyE1MPx

High Comorbidity Rates with Inclusion Body Myositis Guselkumab Treats Axial Disease in Psoriatic Arthritis 11 Drugs That Cause Arthritis https://rheumnow.com/news/11-drugs-ca...

Viewer Question – A positive anti ds DNA in the absence of clinical evidence of lupus?

CONNECT WITH RheumNow

✩ Website - https://rheumnow.com/

✩ Subscribe @ RheumNow: https://rheumnow.com/user/register

✩ LinkedIn - https://www.linkedin.com/in/john-cush...

✩ RheumNow LinkedIn: https://www.linkedin.com/company/rheu...

✩ Twitter - https://twitter.com/RheumNow

Listen | PODCAST

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4Mjzj5j...

Stitcher: https://www.stitcher.com/show/the-rhe...

TuneIn: https://tunein.com/podcasts/Health--W...

Podbean: https://rheumnow.podbean.com/

Got a Rheumatology question or case for Dr. Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.

BackTalk:https://rheumnow.com/submit-podcast-question-or-comment

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

September 17, 2021

New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields.

In this episode, Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80

Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB

MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization ⋗10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F

Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9) https://t.co/fYdH33JbWR

Effect of Diet on COVID Outcomes Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal modelshttps://t.co/MClSjpqpSa

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt

Cases and Questions (AKA Back Talk) “What treatment do you use after 2 years of teraparitide in a woman with a hx of OP, spiral fracture while on a bisphosphonate”? Forteo PI. “Do you have any inside info on the vaccines for COVID-19 during pregnancy?” OCOG Statement “Status of the Tocilizumab Shortage”? Genentech Statement “How would you treat polyarthritis in a renal transplant patient?”

CONNECT WITH RheumNow

✩ Website - https://rheumnow.com/

✩ Subscribe @ RheumNow: https://rheumnow.com/user/register

✩ LinkedIn - https://www.linkedin.com/in/john-cush...

✩ RheumNow LinkedIn: https://www.linkedin.com/company/rheu...

✩ Twitter - https://twitter.com/RheumNow

Listen | PODCAST Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4Mjzj5j...

Stitcher: https://www.stitcher.com/show/the-rhe...

TuneIn: https://tunein.com/podcasts/Health--W...

Podbean: https://rheumnow.podbean.com/

Got a Rheumatology question or case for Dr. Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. BackTalk:

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

September 10, 2021

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com

Rheumatologist Views on new FDA JAK inhibitor Boxed Warnings

Rheumatologist Views on new FDA JAK inhibitor Boxed Warnings

September 3, 2021

Dr. Jack Cush is joined by Drs. Kathryn Dao (Dallas), Rachel Tate (Palm Beach), William Shergy (Huntsville) and Jeffrey Sparks (Boston)

RheumNow Podcast – JAK Inhibitor Warnings from the FDA (9.3.2021)

RheumNow Podcast – JAK Inhibitor Warnings from the FDA (9.3.2021)

September 3, 2021

Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com

Expert Panel Inital Views on FDA Warnings for JAK Inhibitors

Expert Panel Inital Views on FDA Warnings for JAK Inhibitors

September 2, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego)

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

August 27, 2021

Dr. Jack Cush reviews the news, journal reports and cautions regarding COVID-19

RheumNow Podcast – Driving in Pain (8.20.2021)

RheumNow Podcast – Driving in Pain (8.20.2021)

August 20, 2021

Dr. Jack Cush reviews the news, journal articles and more from this past week on RheumNow.com

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

August 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

August 6, 2021

Dr Jack Cush reviews the news, journal reports and FDA approvals from the past week on RheumNow.com

Podbean App

Play this podcast on Podbean App